新指南帮助临床医生使用培米维巴，保护免疫功能低下患者免受新冠病毒感染。 - Suppr

Suppr

超能文献

New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-19.

作者信息

Bock Anna

机构信息

Freelance Journalist, Denver, Colorado.

出版信息

JAMA. 2024 Sep 13. doi: 10.1001/jama.2024.18589.

DOI:10.1001/jama.2024.18589

PMID:39269720

Abstract

摘要

相似文献

New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-19.新指南帮助临床医生使用培米维巴，保护免疫功能低下患者免受新冠病毒感染。

JAMA. 2024 Sep 13. doi: 10.1001/jama.2024.18589.

COVID-19 update: An EUA for pemivibart (Pemgarda) for pre-exposure prophylaxis.2019冠状病毒病最新消息：佩米维巴特（Pemgarda）用于暴露前预防的紧急使用授权。

Med Lett Drugs Ther. 2024 May 13;66(1702):79-80. doi: 10.58347/tml.2024.1702e.

Pemivibart培米维巴

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.替沙格韦单抗和西加韦单抗（Evusheld）用于 1112 例严重免疫功能低下患者的 COVID-19 暴露前预防。

Clin Microbiol Infect. 2022 Dec;28(12):1654.e1-1654.e4. doi: 10.1016/j.cmi.2022.07.015. Epub 2022 Aug 1.

Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study.替沙格韦单抗/西加韦单抗作为严重免疫功能低下患者的 SARS-CoV-2 感染和 COVID-19 重症前暴露预防的疗效：一项单中心、前瞻性、真实世界研究。

Viruses. 2024 Aug 22;16(8):1345. doi: 10.3390/v16081345.

Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations.单克隆抗体作为 COVID-19 预防疗法在免疫功能低下患者人群中的应用。

Int J Infect Dis. 2023 Sep;134:228-238. doi: 10.1016/j.ijid.2023.06.021. Epub 2023 Jul 1.

Polyclonal immunoglobulins for COVID-19 pre-exposure prophylaxis in immunocompromised patients.用于免疫功能低下患者 COVID-19 暴露前预防的多克隆免疫球蛋白。

Transfus Apher Sci. 2023 Jun;62(3):103648. doi: 10.1016/j.transci.2023.103648. Epub 2023 Jan 31.

Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis.接受替沙格韦单抗-西加韦单抗预防的免疫功能低下患者中早发性严重急性呼吸综合征冠状病毒2感染的特征

Open Forum Infect Dis. 2022 Jun 7;9(7):ofac283. doi: 10.1093/ofid/ofac283. eCollection 2022 Jul.

The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.替沙格韦单抗/西加韦单抗（Evusheld）在免疫功能低下患者 COVID-19 预防和治疗中的疗效：系统评价和荟萃分析。

Eur J Med Res. 2024 Jan 5;29(1):27. doi: 10.1186/s40001-023-01549-x.

[Covid-19 in kidney transplant recipients].[肾移植受者中的新冠病毒 19 感染]

Vnitr Lek. 2022 Fall;68(7):444-448. doi: 10.36290/vnl.2022.093.

引用本文的文献

Rapid identification of daratumumab interference with M-protein detection using MALDI-TOF mass spectrometry: a case study involving renal light chain amyloidosis.使用基质辅助激光解吸电离飞行时间质谱快速鉴定达雷妥尤单抗对M蛋白检测的干扰：一例肾轻链淀粉样变性病例研究

Pract Lab Med. 2025 Jul 15;46:e00493. doi: 10.1016/j.plabm.2025.e00493. eCollection 2025 Sep.

SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development.严重急性呼吸综合征冠状病毒2的进化：对诊断、治疗、疫苗有效性及研发的影响

Vaccines (Basel). 2024 Dec 28;13(1):17. doi: 10.3390/vaccines13010017.

Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques.被动输注一种S2茎区广泛中和抗体可保护恒河猴免受SARS-CoV-2感染并减轻下呼吸道炎症。

PLoS Pathog. 2025 Jan 23;21(1):e1012456. doi: 10.1371/journal.ppat.1012456. eCollection 2025 Jan.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验